Recent Posts
- NITYR (nitisinone) Tablets for Tyrosinaemia Type 1 receives Marketing Authorization in New Zealand
- Cycle Announces the Appointment of Angela Kurtz as Clinical Metabolic Director to lead its newly created Clinical Metabolic Department
- Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in Israel
- US FDA Grants Once Daily Dosing Option For NITYR (nitisinone) Tablets for HT-1 Patients
- Dr David Buckeridge Joins Cycle Pharmaceuticals’ Board of Directors
Archives
- No comments have been published yet.
Find us on Facebook
Archives
Recent Posts
- NITYR (nitisinone) Tablets for Tyrosinaemia Type 1 receives Marketing Authorization in New Zealand
- Cycle Announces the Appointment of Angela Kurtz as Clinical Metabolic Director to lead its newly created Clinical Metabolic Department
- Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in Israel
- US FDA Grants Once Daily Dosing Option For NITYR (nitisinone) Tablets for HT-1 Patients
- Dr David Buckeridge Joins Cycle Pharmaceuticals’ Board of Directors
Recent Tweets
-
@steinbg If you are running the Envato Market plugin, disable it, and then try the update again. Also, make sure th… twitter.com/i/web/status/1…
21 hours ago -
What is Conditional Element Rendering in Avada? It is built-in logic that can determine whether a Container or Colu… twitter.com/i/web/status/1…
2 days ago -
Bounce rate & cart abandonment can adversely affect sales & should cause you to rethink your marketing strategy. De… twitter.com/i/web/status/1…
3 days ago
Recent Comments